Reportstack has announced a new market report on PharmaPoint: Alzheimer’s Disease - Japan Drug Forecast and Market Analysis to 2022. There are no long-term effective therapies for Alzheimer’s Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease._x000D_
Aricept is a home-grown product in Japan, and Eisai offers its highest-selling product in additional dosage forms and strengths, which may contribute its rising sales figures. Arimenda will be the first pipeline product to reach the Japanese market and will sustain modest sales throughout the forecast period due to competition from the launch of novel products.
Scope
- Overview of Alzheimer’s Disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape._x000D_
- Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis._x000D_
- Sales forecast for the top drugs in Japan from 2012-2022._x000D_
- Analysis of the impact of key events as well the drivers and restraints affecting Japan Alzheimer’s Disease market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return_x000D_
- Stay ahead of the competition by understanding the changing competitive landscape for Alzheimer’s Disease_x000D_
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential_x000D_
- Make more informed business decisions from insightful and in-depth analysis of drug performance _x000D_
- Obtain sales forecast for drugs from 2012-2022 in Japan.
To view the table of contents and know more details please visit PharmaPoint: Alzheimer’s Disease - Japan Drug Forecast and Market Analysis to 2022 report.
Similar Reports:
No comments:
Post a Comment